Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. - Wikidata - awgldk - TriplyDB

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

http://www.wikidata.org/entity/Q45873929

about

An algorithm for mapping positively selected members of quasispecies-type viruses.Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes Phylogenetic and Genetic Analysis of Feline Immunodeficiency Virus gag, pol, and env Genes from Domestic Cats Undergoing Nucleoside Reverse Transcriptase Inhibitor Treatment or Treatment-Naive Cats in Rio de Janeiro, Brazil Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity Patterns of transmitted HIV drug resistance in Europe vary by risk group Primer and interviews: molecular mechanisms of morphological evolution A fossil record of zidovudine resistance in transmitted isolates of HIV-1 Adaptation of HIV-1 depends on the host-cell environment.Stability analysis of mixtures of mutagenetic trees.Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of India Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors Molecular evidence of HIV-1 transmission in a criminal case.Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1.Orofacial effects of antiretroviral therapies.Zidovudine as modern day salvage therapy for HIV infection.

P2860

Q24797088-D606D85B-D689-48E4-86C6-547D3D3A586C Q26851997-1C2FB1E1-7D51-454A-B73C-4890F1DCBF64 Q27486736-1C71D71D-44CE-4BC0-BB4B-1C701ED10563 Q28316118-0B716258-E1AE-465B-A0AF-1B0299DC35FA Q28326720-82424CD0-D630-495C-B62C-CD8D04C363D7 Q28342745-78E5B7DD-7054-4618-BAD5-8512926DDD2F Q28344137-24682658-6BC0-4AEC-8F36-760EDBEB30E5 Q28367493-25D7A0F4-168A-4966-BC81-4AE42CC7D102 Q28367539-5FDE9434-E73A-4193-9B69-239216697E9C Q28367547-060EB9CC-5FB2-4601-B27E-064D858D34CC Q28367594-B7F3D7D9-901F-4998-8A19-7AB089DA2C73 Q28378547-2C70BEF0-DEE9-44DC-9844-D7AE0E4221ED Q28378611-77D44D03-8AB5-46CE-A854-25B7A4778868 Q28378951-970F04AF-5C1B-4F73-8D4D-180A7FCA7965 Q28379270-8D163B68-629B-4FB1-80B2-4FF452DA3CD1 Q28379499-580D8D93-057D-40E3-8413-E7BAFD2C734E Q28481233-018BA3D3-4B38-4BDD-8577-317A6C6E6F2B Q28481393-646B03A8-421D-4BA5-99E6-160D64ED0EA2 Q28533996-4E3AAF5C-AFF9-4879-A9B9-740A57BB6E2A Q28537726-EC03F9CF-CA79-40A6-8255-EA759A3C0A9A Q28743722-332B4B1B-8C30-490E-83B5-917F5ED47766 Q28775685-0F173ADD-7E3B-4BD1-A4FA-6C00F900D5AD Q33277177-4BE6EC66-2C6C-475D-A437-59FF93B119C4 Q33325781-2547D611-A6F9-4644-A4D2-C8FA5EC4A118 Q33583299-4237F940-BA5C-4085-B061-66B69C423F9D Q33737755-FED29F4F-0A45-4FD3-954C-00B08386207A Q33749177-0D68725C-225D-4B5D-A086-0BDF0DBA9032 Q33782562-0C9DD0B4-B5E2-4438-9B4C-4D37D8565B15 Q33787173-E7B3233D-A56A-4F49-8B74-3C2088565AFC Q33826453-3D13C986-94DB-4A1E-B073-7B321BBE8055 Q33854237-E8B090B5-13AB-42CF-A4D3-7FA0C18ADA85 Q33869951-710DEFE1-6F99-412E-A34E-F986158907AF Q33889635-29A87A50-A394-4636-80E4-CE3BEE6794AE Q33900459-C4C7A225-FEBA-41AA-ACD5-44AAF6A1CC6F Q33906239-035A1A72-C317-45C2-8FD9-AD3E2F70EEF1 Q33982354-96C38CC9-EA02-410D-9E7E-DAB62A9956F5 Q34155272-B25D9EDF-B286-4FC8-B658-F844F9F49A6D Q34252835-D440F592-9126-4CCB-A08A-4C9E6E3CF9C4 Q34383790-3B413504-78A4-4033-B8CB-AA4CA42AD718 Q34436988-BCEF573C-06BF-4A09-B18B-0F2C5F2A3476

P2860

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

http://www.wikidata.org/entity/Q45873929

description

1992 nî lūn-bûn

@nan

1992年の論文

@ja

1992年学术文章

@wuu

1992年学术文章

@zh

1992年学术文章

@zh-cn

1992年学术文章

@zh-hans

1992年学术文章

@zh-my

1992年学术文章

@zh-sg

1992年學術文章

@yue

1992年學術文章

@zh-hant

name

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@en

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@nl

type

label

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@en

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@nl

prefLabel

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@en

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@nl

P1433

Q45873929-F35079B3-A664-46DB-A980-BBF22DDCEDC4

P1476

Q45873929-A15752D0-68A3-4923-A34C-1269D7584C10

P2093

Q45873929-0022E370-7295-448A-A5F6-E91B770EA4C5

Q45873929-03FDA6E8-A52E-47C5-AFCA-135227101E32

Q45873929-10112D5F-9878-43F7-8FCE-1D0364FBFDBD

Q45873929-1B466079-336D-4056-8B78-0957BBFB6F78

Q45873929-59BEDC8A-3C27-4102-97F6-6697E3959D3D

Q45873929-D8A7DFC6-5E45-4927-AF9D-967D0154D840

Q45873929-EAB0F361-4EE1-439B-8A10-ED41321E307A

Q45873929-F4921DAC-34CA-4E29-8BA8-247ACA574A9A

Q45873929-FF2F2B29-0130-4A6A-87F4-263A52F34F42

P304

Q45873929-81B90BDF-763F-4ABB-AFDD-B923022CCB4B

P31

Q45873929-33C98BF9-9A94-4BEA-BB6E-F22960421C3B

P356

Q45873929-6667ECE2-93CB-4093-974A-B007990B8AFE

P407

Q45873929-87FFF69A-193B-42D2-9B83-058F3DA5231E

P433

Q45873929-CD873494-0048-4E92-9CBC-413EAE80982D

P478

Q45873929-62A22148-7290-417C-893D-08CD6C6A5EA9

P577

Q45873929-A9AE7DDB-6BFA-41CA-877F-43641D5BBCED

P698

Q45873929-EE517BA1-0270-4353-9BD1-2A9054F4C986

P356

P1433

The Journal of Infectious Diseases

P1476

Ordered appearance of zidovudi ...... iency virus-positive subjects.

@en

P2093

Boucher CA

http://www.w3.org/2001/XMLSchema#string

Darby G

http://www.w3.org/2001/XMLSchema#string

Goudsmit J

http://www.w3.org/2001/XMLSchema#string

Kellam P

http://www.w3.org/2001/XMLSchema#string

Lange JM

http://www.w3.org/2001/XMLSchema#string

Larder BA

http://www.w3.org/2001/XMLSchema#string

Mulder JW

http://www.w3.org/2001/XMLSchema#string

O'Sullivan E

http://www.w3.org/2001/XMLSchema#string

Ramautarsing C

http://www.w3.org/2001/XMLSchema#string

P304

105-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/165.1.105

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P577

1992-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1370174

http://www.w3.org/2001/XMLSchema#string